Online inquiry

IVTScrip™ mRNA-Anti-MUC1, PankoMab(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ12926MR)

This product GTTS-WQ12926MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets MUC1 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001018016.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 4582
UniProt ID P15941
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-MUC1, PankoMab(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ12926MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ14456MR IVTScrip™ mRNA-Anti-IGF1R, RO4858696-000(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA RO4858696-000
GTTS-WQ2483MR IVTScrip™ mRNA-Anti-CD3E&FOLH1, AMG 212(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA AMG 212
GTTS-WQ1323MR IVTScrip™ mRNA-Anti-MET, ABT-700(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ABT-700
GTTS-WQ7503MR IVTScrip™ mRNA-Anti-HBV, GC-1102(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA GC-1102
GTTS-WQ9158MR IVTScrip™ mRNA-Anti-CD37, IMGN-529(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA IMGN-529
GTTS-WQ15143MR IVTScrip™ mRNA-Anti-FCGRT, SYNT-001(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA SYNT-001
GTTS-WQ11657MR IVTScrip™ mRNA-Anti-HA, MHAA4549A(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA MHAA4549A
GTTS-WQ15942MR IVTScrip™ mRNA-Anti-Felcat NGF, ZTS-00084768(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA ZTS-00084768
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW